According to experts, the blood test may lessen the need for the invasive and dangerous surgery that is currently required to identify certain brain tumors.
Known as a “liquid biopsy,” this test is thought to be the first of its kind in the world and may lessen the need for dangerous and intrusive surgery that is currently required to diagnose certain brain tumors.
According to experts, the tests may also result in an earlier diagnosis, which could expedite treatment and possibly raise survival rates for patients with one of the deadliest types of brain cancer.
Individuals with brain tumors that are incurable may benefit the most since an early diagnosis would enable them to begin treatments like radiation or chemotherapy as soon as possible.
After analyzing the tests, UK scientists hope to carry out more extensive trials.
Experts predict that if the “cheap” and “patient-friendly” test proves effective, health services may implement it in as little as two years.
What is being tested?
Datar Cancer Genetics developed the TriNetra-Glio blood test, which isolates cells that have leaked into a patient’s bloodstream from the tumor.
After being stained, the separated cells are visible under a microscope.
Researchers at Imperial College Healthcare NHS Trust and Imperial College London’s Brain Tumour Research Centre have examined the test.
